Dallas Diabetes Research Center

Recent papers from Dallas Diabetes Research Center

1. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2021
2. Finerenone with empagliflozin according to body mass index in chronic kidney disease and type 2 diabetesEuropean Heart Journal · 2026
3. Piloting a Postdischarge Virtual Glucose Monitoring Program for Patients With Diabetic Foot Wound in a Safety-Net Health SystemJournal of Diabetes Science and Technology · 2026
4. Racial outcomes in patients with diabetic cardiomyopathy treated with an aldose reductase inhibitor: the ARISE-HF trialOpen Heart · 2026
5. Clinical Approaches to Managing Glycemia with the iLet Dosing Decision SoftwareDiabetes Technology and Obesity Medicine · 2026
6. Wcn26-5829 Efficacy and Safety of Finerenone and Empagliflozin in Patients With Initial Decline in Estimated Glomerular Filtration Rate: A Confidence Trial Prespecified AnalysisKidney International Reports · 2026
7. Wcn26-5829 Efficacy and Safety of Finerenone and Empagliflozin in Patients With Initial Decline in Estimated Glomerular Filtration Rate: A Confidence Trial Prespecified AnalysisKidney International Reports · 2026
8. Wcn26-8665 Confidence Asia: Effect of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asian Participants From the Confidence TrialKidney International Reports · 2026
9. Evaluation of Overall Health State, Treatment Burden, and Satisfaction with Insulin Efsitora Alfa (Efsitora) vs. Daily Comparator in Adults with Type 2 Diabetes in the QWINT Clinical Trial ProgramDiabetes Therapy · 2026
10. Comparison of Lean, Obese, and Weight-Loss Models Reveals TREM2 Deficiency Attenuates Breast Cancer Growth Uniquely in Lean Mice and Alters Clonal T-cell PopulationsCancer Research · 2025
11. Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathyCardiovascular Diabetology · 2024
12. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of LinagliptinJAMA Cardiology · 2024
13. Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without DiabetesCirculation · 2022
14. Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 ( BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trialDiabetes Obesity and Metabolism · 2022
15. Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trialDiabetes Obesity and Metabolism · 2022
16. Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled TrialDiabetes Care · 2022
17. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extensionDiabetes Obesity and Metabolism · 2022
18. Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programmeDiabetes Obesity and Metabolism · 2022
19. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without DiabetesJAMA · 2022
20. Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence ResultsDiabetes Therapy · 2021